More than three decades ago, Congress created the 340B program to help safety-net hospitals and clinics expand resources and care for underserved communities. By requiring pharmaceutical companies ...

Drugmakers’ 340B rebate fight, explained Johnson & Johnson, Eli Lilly, Sanofi and Bristol Myers Squibb are suing the federal government over the future of their 340B drug rebate plans.

The past year has seen a great deal of controversy surrounding the 340B Drug Pricing Pr | The 340B drug pricing program has ballooned over the past decade, but the infrastructure to support it has ...

The 340B program is critical to providing health care access to vulnerable Kansans across our state and does so without using any taxpayer dollars.

Although the 340B Drug Pricing Program was intended to lower patient out-of-pocket costs, changing dynamics in the health care space have created provider concerns about whether the plan is working.

A program designed to help poor people afford prescription drugs is being used by hospitals to generate easy profits, according to a Pacific Research Institute report.

Just days and weeks away from key deadlines, the hospital industry’s leading trade organization is still calling for the administration to scrap a one-year pilot of drugmakers’ preferred approach t | ...

The American Hospital Association has sent a letter to Express Scripts asking the pharmacy benefit manager to rescind a policy requiring contract pharmacies to apply a unique code for claims under the ...

The Health Resources and Services Administration reversed a 2020 policy, supported by the hospital industry, that eased 340B certification.